Publications by authors named "Stephanie Aungst"

Claim this Profile
F
FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery.
Michael I Barbato, Amy K Barone, Stephanie L Aungst, Claudia P Miller, Suryatheja Ananthula

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma.
Sonia Singh, Diana Bradford, Somak Chatterjee, Xiaoxue Li, Stephanie L Aungst

Clin Cancer Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.
Michael I Barbato, Diana Bradford, Yi Ren, Stephanie L Aungst, Claudia P Miller

Clin Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations.
Gautam U Mehta, Paz J Vellanki, Yi Ren, Anup K Amatya, Pallavi S Mishra-Kalyani, Stephanie L Aungst

Oncologist· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Katie Chon, Erin Larkins, Somak Chatterjee, Pallavi S Mishra-Kalyani, Stephanie Aungst

Clin Cancer Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
Luckson N Mathieu, Erin Larkins, Oladimeji Akinboro, Pourab Roy, Anup K Amatya, Stephanie Aungst

Clin Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Entrectinib for the Treatment of gene Fusion Solid Tumors.
Leigh Marcus, Martha Donoghue, Stephanie Aungst, Claire E Myers, Whitney S Helms

Clin Cancer Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impaired autophagy flux is associated with neuronal cell death after traumatic brain injury.
Chinmoy Sarkar, Zaorui Zhao, Stephanie Aungst, Boris Sabirzhanov, Alan I Faden

Autophagy· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
Abhilasha Nair, Steven J Lemery, Jun Yang, Anshu Marathe, Liang Zhao, Stephanie Aungst

Clin Cancer Res· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeated mild traumatic brain injury causes chronic neuroinflammation, changes in hippocampal synaptic plasticity, and associated cognitive deficits.
Stephanie L Aungst, Shruti V Kabadi, Scott M Thompson, Bogdan A Stoica, Alan I Faden

J Cereb Blood Flow Metab· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Critical role of trkB receptors in reactive axonal sprouting and hyperexcitability after axonal injury.
Stephanie Aungst, Pamela M England, Scott M Thompson

J Neurophysiol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homeostatic increase in excitability in area CA1 after Schaffer collateral transection in vivo.
Céline Dinocourt, Stephanie Aungst, Kun Yang, Scott M Thompson

Epilepsia· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis